HSBC downgraded Bluebird Bio to Reduce from Buy with a price target of $2.31, down from $4.42.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLUE:
- CRISPR Therapeutics (NASDAQ:CRSP) Tanks after Analyst Downgrade
- Bluebird Bio announces efficacy, safety HRQoL data from sickle cell studies
- Bluebird sinks after Lyfgenia gets boxed warning, review voucher denied
- Bluebird Bio down 35%, halted again for volatility
- Bluebird Bio trading resumes
Questions or Comments about the article? Write to editor@tipranks.com